TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or cytological diagnosis of non-Hodgkin's lymphoma.~2. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.~3. Disease exclusively localized into the central nervous system, cranial nerves or eyes.~4. Untreated patients (patients treated with steroids alone are eligible).~5. At least one measurable lesion.~6. Age 18 - 75 years.~7. ECOG performance status \< 3~8. HBsAg-negative and Ab anti-HCV-negative serologic status.~9. No known HIV disease or immunodeficiency.~10. Adequate bone marrow (PLT \> 100000 mm3, Hb ≥ 9 g/dl, ANC ≥ 2.000 mm3), renal (creatinine clearance ≥ 60 mL/min), cardiac (VEF ≥ 50%), and hepatic function (total serum bilirubin \< 3 mg/dL, AST/ALT and gGT \< 2 per upper normal limit value).~11. No previous or concurrent malignancies with the exception of surgically cured cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer and of other cancers without evidence of disease since at least 5 years (patients with a previous lymphoma diagnosis will be excluded).~12. Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.~13. Non-pregnant and non-lactating status for female patients. Adequate contraceptive measures during study participation for sexually active patients of childbearing potential.~14. No concurrent treatment with other experimental drugs.~15. Informed consent signed by the patient before registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High-dose methotrexate alone (Type: ACTIVE_COMPARATOR): None
- High-dose methotrexate associated with high dose cytarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males ≥ 18 years of age with hemophilia A and residual FVIII levels ≤ 1 IU/dL as evidenced by medical history, at the time of signing the informed consent.~2. Must have been on prophylactic FVIII replacement therapy for at least 12 months prior to study entry.~3. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure days (EDs).~4. No previous documented history of a detectable FVIII inhibitor, and results from a Bethesda assay or Bethesda assay with Nijmegen modification of less than 0.6 Bethesda Units (BU) on 2 consecutive occasions at least one week apart within the past 12 months.~Exclusion Criteria:~1. Detectable pre-existing antibodies to the adeno-associated virus 5 (AAV5) capsid.~2. Any evidence of active infection or any immunosuppressive disorder, except for HIV infection~3. Any evidence of active infection or any immunosuppressive disorder, including HIV infection (effective as of Protocol Amendment 3)~4. Significant liver dysfunction.~5. Prior liver biopsy showing significant fibrosis.~6. Evidence of any bleeding disorder not related to hemophilia A.~7. Platelet count of \< 100 x 10\^9/L.~8. Creatinine ≥ 1.5 mg/dL.~9. Liver cirrhosis of any etiology as assessed by liver ultrasound.~10. Chronic or active hepatitis B.~11. Active Hepatitis C.~12. Active malignancy, except non-melanoma skin cancer.~13. History of hepatic malignancy.~14. History of arterial or venous thromboembolic events.~15. Known inherited or acquired thrombophilia, including conditions associated with increased thromboembolic risk, such as atrial fibrillation.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- valoctocogene roxaparvovec Open Label (Type: EXPERIMENTAL): Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PharmacofMRI of Anxiolytic Medications (Pregabalin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male, or female (not pregnant or intending to become pregnant during the study)~* Between the ages of 18-30.~* In good general health.~* No specific contraindications to the drug being administered~Exclusion Criteria:~* Subjects with a history of DSM-IV depressive disorder, psychotic disorder, anxiety disorder~* Subjects who meet criteria for substance abuse or dependence within the last 6 months~* Subjects with an positive urine screen for illicit drugs having clinically significant abnormal laboratory, ECG or physical examination findings not resolved by the baseline visit~* Patients who have taken psychotropic drugs or antidepressants (including monoamine oxidase inhibitors, MAOI's) within the last year~* Subjects who are left-handed.~* Subjects suffering suffers from claustrophobia, or phobia for injections or blood~* Magnetic Resonance Imaging related exclusion criteria: cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), subjects who have ever been a metal worker/welder; history of eye surgery/eyes washed out because of metal, aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, subjects who are in the first trimester of pregnancy, subjects with an I.U.D. (birth control device), a shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Pregabalin 50 mg (Type: ACTIVE_COMPARATOR): Pregabalin oral tablets (50 mg)
- Pregabalin 200 mg (Type: ACTIVE_COMPARATOR): Pregabalin oral tablets (200 mg)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have histologically or cytologically confirmed Acute Myeloid Leukemia, as defined by the WHO classification.~2. Patients must be considered unfit for conventional induction chemotherapy, unwilling to receive such treatment or have evidence of disease relapse or refractory disease.~3. For patients who have received no prior conventional chemotherapy, one of the following must be present:~   * Poor risk cytogenetics (complex abnormalities, deletions of chromosome 7 or 5, 11q23 abnormalities, inv\[3\])~  * Secondary leukemia (prior hematologic disorder or therapy-related leukemia).~4. Age \> 60 years of age.~5. Life expectancy of greater than 3 months.~6. ECOG performance status greater than 2.~7. Patients must have normal organ and marrow function as defined below:~8. Adequate hepatic function: Total bilirubin 1.5mg/dL, AST(SGOT)/ALT(SGPT) 2.5 X institutional upper limit of normal.~9. Adequate renal function: serum creatinine within normal institutional limits or Calculated creatinine clearance \> 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.~10. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.~2. Patients may not be receiving any other investigational agents.~3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or DTIC~4. History of gastrointestinal disease or significant bowel resection that could interfere with drug absorption.~5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~6. Prior allogeneic stem cell transplantation.~7. Inability to swallow tablets~8. Prior radiation up to more than 25% of bone marrow.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylated AGAT Promoter (Group 1) (Type: EXPERIMENTAL): Induction: 200 mg/m2/day oral Temozolomide x 7 days
- Un-Methylated AGAT Promoter (Group 2) (Type: EXPERIMENTAL): Priming: 100 mg/m2/day oral Temozolomide x 14 days, followed by Induction: 200 mg/m2/day oral Temozolomide x 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has oral mucositis pain that is grade 3 or 4 according to the World Health Organization (WHO) Oral Mucositis Scale~* Patient has received at least one prior chemotherapy or radiation treatment~* Patient is at least 18 years old~* Patient or their legally authorized representative understands and voluntarily signs the written informed consent prior to any study-specific procedures. A copy of the signed informed consent form will be retained by the treating institution.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Ketamine oral mouthwash 20mg/5ml swish and spit four times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age ≥ 18 years old admitted to San Francisco General Hospital for injury with at least one risk factor for venous thromboembolism (VTE).~Risk factors are: Age ≥ 40 years, pelvic fracture, lower extremity fracture, spinal cord injury, shock or head injury, major operative procedure, mechanical ventilation \> 3 days, venous injury~Exclusion Criteria:~* prisoners~* pregnant patients~* patients who are anticipated to have a \< 5 day length of stay as determined by the admitting trauma surgeon~* patients who decline to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1A (Type: EXPERIMENTAL): Patients at high risk for venous thromboembolism (criteria: age\>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with Abbreviated Injury Scale (AIS) \>=3). These patients will receive fondaparinux 2.5mg via subcutaneous administration (SubQ) daily.
- 1B (Type: ACTIVE_COMPARATOR): Patients at high risk for venous thromboembolism (criteria: age\>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS \>=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance \<30 mL/min, head injury with head AIS \>=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
- 2A (Type: EXPERIMENTAL): Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days \>3, 2 or more high risk factors). These patients will receive fondaparinux 2.5mg SubQ daily and mechanical compression.
- 2B (Type: ACTIVE_COMPARATOR): Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days \>3, 2 or more high risk factors) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure creatine clearance \<30 mL/min, head injury with head AIS \>=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression and possibly temporary inferior vena cava (IVC) filter(as determined by the patient's care givers).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic leiomyosarcoma (uterus or soft tissue) in inoperable relapse with no previous chemotherapy~* At least one measurable lesion according to RECIST criteria before inclusion. At least one of the target is in a none irradiated area~* Aged \>/= 18 years and physiological age \</= 70 years~* PS \</= 2~* Normal hematological function (Polymorphonuclear Neutrophils \>/= 1500/mm3, platelets \>/= 100 000/mm3)~* Normal kidney function (creatinine \< 1.5xN)~* Creatinine phosphokinase \</= 2.5xN~* Normal hepatic function (total bilirubin \</= 1xN; transaminase \</= 2.5xN and alkaline phosphatase \</= 1.5xN)~* Cardiac function: normal echography and/or isotopic ventriculography (FR\>30%, FEVG \> 50%)~* Patients able to procreate must use a birth control device during treatment and during 3 months after treatment for women; 5 months for men~* Signed informed consent~* Patient under affiliated to a system of care~Exclusion Criteria:~* Any other histological type of uterus sarcoma (carcinosarcoma...) or soft tissue~* Specific contraindication to the treatment~* Previous or evolutive mental disease~* Previous cancer~* Symptomatic or known brain metastasis~* Previous radiotherapy ont he only measurable lesion~* Previous allograft or autograft~* Known positive serology (HIV, HbC, HbS)~* Pregnant or breastfeeding women~* Impossibility to follow the treatment for geographical, social or mental reason~* Patients under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Soft tissue (Type: EXPERIMENTAL): None
- Uterus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female of non child bearing potential~* Clinical diagnosis of bronchiectasis~* Be sputum producers, with history of chronic expectoration on most days~Exclusion Criteria:~* Concomitant diagnosis of pulmonary disease other than bronchiectasis or COPD~* FEV1 of \<30% of predicted normal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AZD9668 active treatment (Type: EXPERIMENTAL): None
- AZD9668 placebo treatment (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Left atrial AF ablation procedure requiring the use of a Lasso mapping catheter~* Subject must be at least 18 years of age~* Subject must be male, female of no childbearing potential, or a female that has a negative pregnancy test prior to randomization~Exclusion Criteria:~* Unable to safely expose subject to a magnetic field~* Prior AF ablation procedure~* Patients with fewer than 4 PVs are excluded~* Patients with persistent AF in whom early recurrence of AF following cardioversion would preclude completion of the pacing maneuvers described in the protocol or patients with other conditions that would similarly preclude completion of the pacing maneuvers~* Contraindication to procedure or unable to return for follow-up~* History of clotting disorder, bleeding abnormalities or contraindication to anticoagulation~* Actively participating in other cardiac device trial(s)~* Currently pregnant~* Under 18 years of age~* Prosthetic valves~* Atrial abnormalities (thrombus, myxoma or baffle)~* Other exclusions per the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Manual Lasso navigation (Type: ACTIVE_COMPARATOR): Use of conventional manual navigation techniques with the Lasso catheter
- Vdrive Lasso navigation (Type: EXPERIMENTAL): Use of the Vdrive to remotely and robotically control the manipulation of a Lasso catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Competent and capable to provide informed consent~* • Positive molecular test for presence of SARS-CoV-2 in fluid collected by saliva for antigen, oropharyngeal or nasopharyngeal swab~* Experiencing any symptoms of COVID-19 including but not limited to fever(T\> 100.5º F), cough, or other COVID associated symptoms like anosmia~* ≤ 8 days since the first symptoms of COVID-19~* ≤ 8 days since first positive SARS-CoV-2 RNA test~* Able and willing to comply with protocol requirements listed in the informed consent~Exclusion Criteria:~* Hospitalized or expected to be hospitalized within 24 hours of enrollment~* Psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance~* History of prior reactions to transfusion blood products~* Inability to complete therapy with the study product within 24 hours after enrollment~* Receiving any treatment drug for COVID-19 within 14 days prior to screening evaluation (monoclonal antibodies, compassionate use or study trial related). Steroid treatment at any time does not affect study eligibility

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SARS-CoV-2 convalescent plasma (Type: EXPERIMENTAL): SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
- Standard Control plasma (Type: ACTIVE_COMPARATOR): Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete